$OPCH

Option Care Health, Inc. (OPCH): Entry into a Material Definitive Agreement

Option Care Health, Inc. (OPCH) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 CD&R and McKesson Corporation Sign Agreement to Acquire Option Care Health NEW YORK, IRVING, Texas and BANNOCKBURN, Ill., October 6, 2026 — CD&R, McKesson Corporation (NYSE: MCK) (“McKesson”), and Option Care Health, Inc. (Nasdaq: OPCH) (“Option Care Health”) announc

Original reporting
Published Oct 6, 2026, 12:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 12:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$OPCH
Neutral
high confidence
Mentioned
$OPCH · $MCK
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$OPCHNeutralHigh
01

Why it matters

The deal sets a $5.8 B valuation for the home‑infusion market and signals McKesson's deeper entry into specialty therapy delivery.

02

Market read

The announcement is a primary M&A disclosure with material impact on the involved stocks and the broader healthcare services sector.

03

What to watch

Potential integration challenges and reimbursement uncertainties for complex specialty therapies.

Relevance 6/10Novelty 9/10Timing: today

Background

The filing is an SEC Form 8‑K announcing the first public details of the acquisition.

Company-level read

Ticker impact

$OPCHNeutralHigh confidence
Context

Option Care Health announced a definitive agreement to be acquired for $32.05 per share, $5.8 B total value, and will be delisted from Nasdaq.

Expected impact

likely pressure as the market prices in the $32.05 offer, modest upside only if the deal closes at a higher price.

Evidence & confidence

The deal is already disclosed with a 37% premium; investors will adjust the price to the offer level, reducing speculative upside.

$MCKNeutralMedium confidence
Context

McKesson Corporation will invest about $1.4 B for a 49% minority stake in Option Care Health as part of the acquisition.

Expected impact

slight pressure or flat as the market digests the investment cost versus strategic benefit.

Evidence & confidence

The strategic rationale is positive, yet the sizable cash commitment could temper short‑term price movement.

Market effects

Consolidation in the home and alternate site infusion services sector may lift valuations of peers.

Adds to US healthcare services M&A activity, influencing related stocks.

Highlights continued strategic investment in specialty therapy delivery worldwide.

Counterpoint

If the acquisition faces regulatory delays, Option Care Health shares could fall below the offer price.

Key entities

  • Option Care Health

    Provider of home and alternate site infusion services, target of acquisition.

  • McKesson Corporation

    Healthcare services and pharmaceutical distribution company acquiring a minority stake.

  • CD&R

    Private investment firm taking majority ownership of Option Care Health.

Related articles

$OPCHMed

Key deals this week: Option Care Health, PTC, Energy Transfer and more

Service Properties Trust (SSVC) received a $2.0B acquisition offer from TKO LLC. Viatris (VTRS) agreed to buy Pacira BioSciences (PCRX) for $1.65B. Option Care Health (OPCH) surged 34% after a $5.8B acquisition deal with CD&R and McKesson (MCK). Energy Transfer (ET) will acquire Vaquero Midstream for $2.625B. Emera (EMA) and Canadian Utilities (CDUAF) agreed to a $10B merger. Cenovus Energy (CVE) will acquire Athabasca Oil (ATHOF) for ~$5.7B.

$OPCHHighAI 9/10

Option Care Health Sold for $5.8B in CD&R-McKesson Deal

Option Care Health (OPCH) is being acquired by CD&R and McKesson (MCK) for $5.8B, or $32.05 per share, a 37% premium. The deal, expected to close in 2027, values the company at $5.8B. Option Care Health will operate independently post-acquisition. The company reported $5.6B in 2025 revenue and $207.6M in net income, with modest growth in 2026. The acquisition aligns with McKesson's strategy to expand access to innovative therapies.

$MCKHighAI 9/10

McKesson (MCK) Joins $5.8 Billion Option Care Health (OPCH) Acquisition. Is the Valuation Justified?

McKesson (MCK) is acquiring Option Care Health (OPCH) for $5.8B, including debt, at $32.05 per share, a 37% premium. McKesson and private equity firm CD&R will own 49% and 51% respectively. The deal expands McKesson's specialty healthcare services. McKesson's Q1 2027 revenue was $105.4B, beating estimates, with adjusted EPS up 20% YoY to $9.93. The company raised its fiscal 2027 adjusted EPS guidance to $44.20-$45.00.

$MCKHighAI 9/10

McKesson & CD&R Acquire Leading US Home-Infusion Platform

McKesson and private equity firm CD&R will acquire Option Care Health, a US home-infusion care provider, for $5.8bn. CD&R will take a majority stake, while McKesson invests $1.4bn for a minority stake. The deal values Option Care Health at $32.05 per share and is expected to close in H1 2027. McKesson aims to leverage the acquisition to expand its specialty care offerings.

$OPCHHighAI 9/10

Infusion therapy provider being acquired in $5.8 billion deal

Option Care Health (OPCH) is being acquired by CD&R and McKesson in a $5.8 billion deal, expected to close in early 2027. CD&R will hold majority ownership, with McKesson holding a minority stake. Option Care Health shares were trading at $31.02, up from $23.34 before the acquisition news. The company will remain separate but will delist from Nasdaq post-deal.